5-fluorouracil and interferon-α immunochemotherapy enhances immunogenicity of murine pancreatic cancer through upregulation of NKG2D ligands and MHC class i

Journal of Immunotherapy

Volumn 35, Issue 3, 2012, Pages 245-253

  Khallouf, Hadeel ^a,b   Märten, Angela ^a   Serba, Susanne ^a   Teichgräber, Volker ^b   Büchler, Markus W ^a   Jäger, Dirk ^b   Schmidt, Jan ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

5 fluorouracil; immunochemotherapy; interferon a; pancreatic cancer

Indexed keywords

FLUOROURACIL; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NATURAL KILLER CELL RECEPTOR NKG2D;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL ISOLATION; CONTROLLED STUDY; DENDRITIC CELL; DRUG CYTOTOXICITY; FLOW CYTOMETRY; IMMUNOGENICITY; LYMPHOCYTIC INFILTRATION; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; T CELL DEPLETION; UPREGULATION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; DENDRITIC CELLS; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; H-2 ANTIGENS; INTERFERON-ALPHA; KILLER CELLS, NATURAL; LYMPHOCYTE DEPLETION; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; PANCREATIC NEOPLASMS;

EID: 84858755173     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31824b3a76     Document Type: Article

References (40)

1. Li D, Xie K, Wolff R, et al. Pancreatic cancer. Lancet. 2004;363:1049-1057. (Pubitemid 38410779)
2. Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer. 2002;2:897-909. (Pubitemid 37328891)
3. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200-1210. (Pubitemid 38339364)
4. Laheru D, Jaffee EM. Immunotherapy for pancreatic cancer-science driving clinical progress. Nat Rev Cancer. 2005;5: 459-467. (Pubitemid 40791488)
5. Laheru D, Biedrzycki B, Jaffee EM. Immunologic approaches to the management of pancreatic cancer. Cancer J. 2001;7: 324-337.
6. Gutterman JU. Cytokine therapeutics lessons from interferon alpha. Proc Natl Acad Sci USA. 1994;91:1198-1205. (Pubitemid 24058977)
7. Paquette RL, Hsu NC, Kiertscher SM, et al. Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigenpresenting cells. J Leukoc Biol. 1998;64:358-367. (Pubitemid 28409243)
8. Marrack P, Kappler J, Mitchell T. Type I interferons keep activated T cells alive. J Exp Med. 1999;189:521-530.
9. Pfeffer LM, Dinarello CA, Herberman RB, et al. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res. 1998;58:2489-2499. (Pubitemid 28275413)
10. Decatris M, Santhanam S, O'Byrne K. Potential of interferonalpha in solid tumours: part 1. BioDrugs. 2002;16:261-281.
11. Hoffmann K, Mehrle S, Schmidt J, et al. Interferon-alpha restitutes the chemosensitivity in pancreatic cancer. Anticancer Res. 2008;28:1499-1507. (Pubitemid 351892922)
12. Zhu Y, Tibensky I, Schmidt J, et al. Interferon-alpha in combination with chemotherapy has potent antiangiogenic properties in an orthotopic mouse model for pancreatic adenocarcinoma. J Immunother. 2008;31:28-33. (Pubitemid 351619401)
13. Picozzi VJ, Kozarek RA, Traverso LW. Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg. 2003;185: 476-480. (Pubitemid 36513960)
14. Knaebel HP, Marten A, Schmidt J, et al. Phase III trial of postoperative cisplatin, interferon alpha-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma-CapRI: study protocol [ISRCTN62866759]. BMC Cancer. 2005;5:37.
15. Ma JH, Patrut E, Schmidt J, et al. Synergistic effects of interferon-alpha in combination with chemoradiation on human pancreatic adenocarcinoma. World J Gastroenterol. 2005;11:1521-1528. (Pubitemid 40468089)
16. Zhu Y, Tibensky I, Schmidt J, et al. Interferon-alpha enhances antitumor effect of chemotherapy in an orthotopic mouse model for pancreatic adenocarcinoma. J Immunother. 2008;31: 599-606.
17. Schmidt J, Patrut EM, Ma J, et al. Immunomodulatory impact of interferon-alpha in combination with chemoradiation of pancreatic adenocarcinoma (CapRI). Cancer Immunol Immunother. 2006;55:1396-1405. (Pubitemid 44187671)
18. Hochweller K, Striegler J, Hammerling GJ, et al. A novel CD11c.DTR transgenic mouse for depletion of dendritic cells reveals their requirement for homeostatic proliferation of natural killer cells. Eur J Immunol. 2008;38:2776-2783.
19. Gromme M, Neefjes J. Antigen degradation or presentation by MHC class I molecules via classical and non-classical pathways. Mol Immunol. 2002;39:181-202. (Pubitemid 35013511)
20. Belardelli F, Ferrantini M, Proietti E, et al. Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 2002;13:119-134. (Pubitemid 34229387)
21. Ohtsukasa S, Okabe S, Yamashita H, et al. Increased expression of CEA and MHC class I in colorectal cancer cell lines exposed to chemotherapy drugs. J Cancer Res Clin Oncol. 2003;129:719-726. (Pubitemid 38002303)
22. Kä rre K, Ljunggren HG, Piontek G, et al. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature. 1986;319:675-678. (Pubitemid 16119452)
23. Litwin V, Gumperz J, Parham P, et al. Specificity of HLA class I antigen recognition by human NK clones: evidence for clonal heterogeneity, protection by self and non-self alleles, and influence of the target cell type. J Exp Med. 1993;178: 1321-1336. (Pubitemid 23277364)
24. Bakker AB, Wu J, Phillips JH, et al. NK cell activation: distinct stimulatory pathways counterbalancing inhibitory signals. Hum Immunol. 2000;61:18-27. (Pubitemid 30058763)
25. Raulet DH. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol. 2003;3:781-790. (Pubitemid 37328656)
26. Diefenbach A, Jamieson AM, Liu SD, et al. Ligands for the murine NKG2D receptor expression by tumor cells and activation of NK cells and macrophages. Nat Immunol. 2000;1: 119-126.
27. Carayannopoulos LN, Naidenko OV, Fremont DH, et al. Cutting edge: murine UL16-binding protein-like transcript 1: a newly described transcript encoding a high-affinity ligand for murine NKG2D. J Immunol. 2002;169:4079-4083. (Pubitemid 35178173)
28. Pende D, Rivera P, Marcenaro S, et al. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res. 2002;62:6178-6186. (Pubitemid 35244469)
29. Salih HR, Antropius H, Gieseke F, et al. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood. 2003;102:1389-1396. (Pubitemid 36988048)
30. Raffaghello L, Prigione I, Airoldi I, et al. Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma. Neoplasia. 2004;6:558-568. (Pubitemid 39411093)
31. Diefenbach A, Jensen ER, Jamieson AM, et al. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature. 2001;413:165-171. (Pubitemid 32867877)
32. Cerwenka A, Baron JL, Lanier LL. Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc Natl Acad Sci USA. 2001;98:11521-11526. (Pubitemid 32928761)
33. Guerra N, Tan YX, Joncker NT, et al. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity. 2008;28:571-580.
34. McGilvray RW, Eagle RA, Watson NF, et al. NKG2D ligand expression in human colorectal cancer reveals associations with prognosis and evidence for immunoediting. Clin Cancer Res. 2009;15:6993-7002.
35. Gasser S, Orsulic S, Brown EJ, et al. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature. 2005;436:1186-1190. (Pubitemid 41232299)
36. Jinushi M, Takehara T, Tatsumi T, et al. Autocrine/paracrine IL-15 that is required for type I IFN-mediated dendritic cell expression of MHC class I-related chain A and B is impaired in hepatitis C virus infection. J Immunol. 2003;171:5423-5429. (Pubitemid 37432829)
37. Adam C, King S, Allgeier T, et al. DC-NK cell cross talk as a novel CD4+ T-cell-independent pathway for antitumor CTL induction. Blood. 2005;106:338-344. (Pubitemid 40967210)
38. Galetto A, Buttiglieri S, Forno S, et al. Drug-and cellmediated antitumor cytotoxicities modulate cross-presentation of tumor antigens by myeloid dendritic cells. Anticancer Drugs. 2003;14:833-843. (Pubitemid 38339789)
39. Tanaka F, Yamaguchi H, Ohta M, et al. Intratumoral injection of dendritic cells after treatment of anticancer drugs induces tumor-specific antitumor effect in vivo. Int J Cancer. 2002;101: 265-269. (Pubitemid 34970895)
40. Koike K, Takaki A, Tatsukawa M, et al. Combination of 5-FU and IFNalpha enhances IFN signaling pathway and caspase-8 activity, resulting in marked apoptosis in hepatoma cell lines. Int J Oncol. 2006;29:1253-61.